Diehl Christian D, Giordano Frank A, Grosu Anca-L, Ille Sebastian, Kahl Klaus-Henning, Onken Julia, Rieken Stefan, Sarria Gustavo R, Shiban Ehab, Wagner Arthur, Beck Jürgen, Brehmer Stefanie, Ganslandt Oliver, Hamed Motaz, Meyer Bernhard, Münter Marc, Raabe Andreas, Rohde Veit, Schaller Karl, Schilling Daniela, Schneider Matthias, Sperk Elena, Thomé Claudius, Vajkoczy Peter, Vatter Hartmut, Combs Stephanie E
Department of Radiation Oncology, Technical University of Munich (TUM), Klinikum rechts der Isar, 81675 München, Germany.
Institute of Radiation Medicine (IRM), Helmholtz Zentrum München, 85764 Neuherberg, Germany.
Cancers (Basel). 2023 Jul 19;15(14):3670. doi: 10.3390/cancers15143670.
Postsurgical radiotherapy (RT) has been early proven to prevent local tumor recurrence, initially performed with whole brain RT (WBRT). Subsequent to disadvantageous cognitive sequalae for the patient and the broad distribution of modern linear accelerators, focal irradiation of the tumor has omitted WBRT in most cases. In many studies, the effectiveness of local RT of the resection cavity, either as single-fraction stereotactic radiosurgery (SRS) or hypo-fractionated stereotactic RT (hFSRT), has been demonstrated to be effective and safe. However, whereas prospective high-level incidence is still lacking on which dose and fractionation scheme is the best choice for the patient, further ablative techniques have come into play. Neoadjuvant SRS (N-SRS) prior to resection combines straightforward target delineation with an accelerated post-surgical phase, allowing an earlier start of systemic treatment or rehabilitation as indicated. In addition, low-energy intraoperative RT (IORT) on the surgical bed has been introduced as another alternative to external beam RT, offering sterilization of the cavity surface with steep dose gradients towards the healthy brain. This consensus paper summarizes current local treatment strategies for resectable brain metastases regarding available data and patient-centered decision-making.
Curr Oncol. 2007-8
Radiat Oncol. 2021-4-15
Technol Cancer Res Treat. 2002-2
Cancer Pathog Ther. 2023-12-2
Front Oncol. 2022-5-4
Front Oncol. 2022-2-18
Curr Oncol Rep. 2022-3